Journal
NATURE MEDICINE
Volume 24, Issue 11, Pages 1752-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-018-0207-3
Keywords
-
Funding
- NIH [1U10CA180886-01, 1R01CA155360, R01 CA114567]
- Seattle Run of Hope
- Seattle Children's Brain Tumor Research Endowment
- Dutch Cancer Foundation KWF [2010-4713]
- Dutch Cancer Foundation KIKA [90]
- Deutsche Krebshilfe [111537]
- BMBF [01KT1605]
- Helmholtz International Graduate School for Cancer Research
- IMI-JUITCC-P4 [116064]
Ask authors/readers for more resources
Brain tumors are the leading cause of cancer-related death in children. Genomic studies have provided insights into molecular subgroups and oncogenic drivers of pediatric brain tumors that may lead to novel therapeutic strategies. To evaluate new treatments, better preclinical models adequately reflecting the biological heterogeneity are needed. Through the Children's Oncology Group ACNS02B3 study, we have generated and comprehensively characterized 30 patient-derived orthotopic xenograft models and seven cell lines representing 14 molecular subgroups of pediatric brain tumors. Patient-derived orthotopic xenograft models were found to be representative of the human tumors they were derived from in terms of histology, immunohistochemistry, gene expression, DNA methylation, copy number, and mutational profiles. In vivo drug sensitivity of targeted therapeutics was associated with distinct molecular tumor subgroups and specific genetic alterations. These models and their molecular characterization provide an unprecedented resource for the cancer community to study key oncogenic drivers and to evaluate novel treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available